Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis Genzyme, 11 Jul 2011 Accessed on 6 Dec 2011 from http://www.businesswire.com/news/genzyme/20110710005114/en. CommentRecommendBookmarkWatch